Cancers among HIV-infected Persons

Infectious Diseases in Clinical Practice

Volumn 14, Issue 5, 2006, Pages 258-265

  Crum Cianflone, Nancy F ^a   Burgi, Alina ^b  

^a NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; ANTIVIRUS AGENT; HEMOPOIETIC GROWTH FACTOR; HEPATITIS B VACCINE; IMMUNOSUPPRESSIVE AGENT; PROTEINASE;

ANUS CANCER; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; COLON CANCER; DISEASE ASSOCIATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LEUKEMIA; LUNG CANCER; MASS SCREENING; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; PROSTATE CANCER; REVIEW; SKIN CANCER; UTERINE CERVIX CANCER; VACCINATION;

EID: 33748788246     PISSN: 10569103     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.idc.0000217666.51001.c2     Document Type: Review

References (71)

1. Centers for Disease Control and Prevention (CDC). Update on acquired immune deficiency syndrome (AIDS) - United States. MMWR Morb Mort Wkly Rep. 1982;31:507-514.
2. Centers for Disease Control and Prevention (CDC). 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep. 1992;41:961-962.
3. Monfardini S, Vaccher E, Pizzocaro G, et al. Unusual malignant tumours in 49 patients with HIV infection. AIDS. 1989;3:449-452.
4. Palella FJ Jr, Baker R, Moorman AC, et al. Mortality and morbidity in the HAART era: changing causes of death and disease in the HIV outpatient study. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, CA. Abstract 872.
5. Bonnet F, Morlat P, Chene G, et al. Causes of death among HIV-infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998-1999. HIV Med. 2002;3:195-199.
6. Cohen MH, French AL, Benning L, et al. Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 2002;113:91-98.
7. Valdez H, Chowdhry TK, Asaad R, et al. Changing spectrum of mortality due to human immunodeficiency virus: analysis of 260 deaths during 1995-1999. Clin Infect Dis. 2001;32:1487-1493.
8. Mocroft A, Brettle R, Kirk O, et al. Changes in the cause of death among HIV positive subjects across Europe: results from the EuroSIDA study. AIDS. 2002;16:1663-1671.
9. Bonnet F, Lewden C, May T, et al. Malignancy-related causes of death in human immunodeficiency virus-infected patients in the era of highly active antiretroviral therapy. Cancer. 2004;101:317-324.
10. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst. 2000;92:1823-1830.
11. Stein M, O'Sullivan P, Wachtel T, et al. Causes of death in persons with human immunodeficiency virus infection. Am J Med. 1992;93:387-390.
12. Herida M, Mary-Krause M, Kaphan R, et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J Clin Oncol. 2003;21:34453-34477.
13. Bedimo R, Chen RY, Accortt NA, et al. Trends in AIDS-defining and non-AIDS-defining malignancies among HIV-infected patients: 1989-2002. Clin Infect Dis. 2004;39:1380-1384.
14. Dal Maso L, Franceschi S, Polesel J, et al. Risk of cancer in persons with AIDS in Italy, 1985-1998. Br J Cancer. 2003;89:94-100.
15. Frisch M, Biggar RJ, Engels EA, et al. Association of cancer with AIDS-related immunosuppression in adults. JAMA. 2001;245:1736-1745.
16. Goedert JJ, Cote TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet. 1998;351:1833-1839.
17. Serraino D, Boschini A, Carrieri P, et al. Cancer risk among men with, or at risk of, HIV infection in southern Europe. AIDS. 2000;14:553-559.
18. Mbulaiteye SM, Biggar RJ, Goedert JJ, et al. Immune deficiency and risk for malignancy among persons with AIDS. J Acquir Immune Defic Syndr. 2003;32:527-533.
19. Gallagher B, Wang Z, Schymura MJ, et al. Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol. 2001;154:544-556.
20. Pollock BH, Jenson HB, Leach CT. Risk factors for pediatric human immunodeficiency virus-related malignancy. JAMA. 2003;289:2393-2399.
21. Saves M, Chene G, Ducimetiere P, et al. Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared to the general population. Clin Infect Dis. 2003;37:292-298.
22. De Falco G, Bellan C, Lazzi S, et al. Interaction between HIV-1 Tat and pRb2/p130: a possible mechanism in the pathogenesis of AIDS-related neoplasms. Oncogene. 2003;22:6214-6219.
23. Clifford G, Polesel J, Rickenbach M, et al. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J Natl Cancer Inst. 2005;97:425-432.
24. Laurence J. Impact of HAART on HIV-linked malignancies. AIDS Read. 2003;13:202-205.
25. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet. 1999;353(13):863-868.
26. Burgi A, Brodine S, Wegner S, et al. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals. Cancer. 2005;104:1505-1511.
27. Mbulaiteye SM, Katabira ET, Wabinga H, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDS-cancer registry match study. Int J Cancer. 2006;118:985-990.
28. Newnham A, Harris J, Evans HS, et al. The risk of cancer in HIV-infected people in southeast England. A cohort study. Br J Cancer. 2005;92:194-200.
29. Grulich AE, Li Y, McDonald A, et al. Rates of non-AIDS-defining cancers in people with HIV infection before and after AIDS diagnosis. AIDS. 2002;16(8):1155-1161.
30. Cheung MC, Pantanowitz L, Dezube BJ. AIDS-related malignancies: emerging challenges in the era of highly active antiretroviral therapy. Oncologist. 2005;10:412-426.
31. Portsmouth S, Stebbing J, Gill J, et al. A comparison of regimens based on non-nucleoside reverse transcriptase inhibitors or protease inhibitors in preventing Kaposi's sarcoma. AIDS. 2003;17:F17-F22.
32. Spano JP, Atlan D, Breau JL, et al. AIDS and non-AIDS-related malignancies: a new vexing challenge in HIV-positive patients. Part I: Kaposi's sarcoma, non-Hodgkin lymphoma, and Hodgkin's lymphoma. Eur J Intern Med. 2002;13:170-179.
33. Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international prospective. Hematol Oncol Clin North Am. 2003;17:673-696.
34. Grulich AE, Wan X, Law MG, et al. B-cell stimulation and prolonged immune deficiency are risk factors for non-Hodgkin's lymphoma in people with AIDS. AIDS. 2000;14:133-140.
35. Fan H, Kim SC, Chukwuemeka OC, et al. Epstein-Barr viral load as a marker of lymphoma in AIDS patients. J Med Virol. 2005;75:59-69.
36. Jacobson LP, Yamashita TE, Detels R, et al. Impact of potent antiretroviral therapy on the incidence of Kaposi's sarcoma and non-Hodgkin's lymphoma among HIV-1 infected individuals. Multicenter AIDS Cohort Study. J Acquir Immune Defic Syndr Hum Retrovirol. 1999;21:S34-S41.
37. Besson C, Goubar A, Gabarre J, et al. Changes in AIDS-related lymphoma since the era of highly active antiretroviral therapy. Blood. 2001;98:2339-2344.
38. Diamond C, Taylor TH, Aboumrad T, et al. Changes in acquired immunodeficiency syndrome-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy. Cancer. 2006;106:128-135.
39. Franceschi S, Dal Maso L, Pezzotti P, et al. Incidence of AIDS-defining cancers after AIDS diagnosis among people with AIDS in Italy, 1986-1998. J Acquir Immune Defic Syndr. 2003;34:84-90.
40. Aboulafia DM, Pantanowitz L, Dezube BJ. AIDS-related non-Hodgkin lymphoma: still a problem in the era of HAART. AIDS Read. 2004;14:605-617.
41. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst. 2000;92:1500-1510.
42. Robertson P, Scadden DT. Immune reconstitution in HIV infection and its relationship to cancer. Hematol Oncol Clin North Am. 2003;17:703-716.
43. Palefsky JM, Holly EA, Ralson ML, et al. High incidence of anal high-grade squamous intraepithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS. 1998;12:495-503.
44. Piketty C, Darragh TM, Da Costa M, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;183:453-459.
45. Melbye M, Cote TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. Lancet. 1994;343:636-639.
46. Piketty C, Darragh TM, Heard I, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31:96-99.
47. Franceschi S, Dal Maso L, Arniani S. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Br J Cancer. 1998;78:966-970.
48. Vilchez RA, Finch CJ, Jorgensen JL, et al. The clinical epidemiology of Hodgkin lymphoma in HIV-infected patients in the highly active antiretroviral therapy (HAART) era. Medicine. 2003;82:77-81.
49. Tirelli U, Spina M, Sandri S, et al. Lung carcinoma in 36 patients with human immunodeficiency virus infection. The Italian Cooperative Group on AIDS and Tumors.. Cancer. 2000;88:563-569.
50. Spano JP, Massiani MA, Bentata M, et al. Lung cancer in patients with HIV infection and review of the literature. Med Oncol. 2004;21:109-115.
51. Remick SC. Non-AIDS-defining cancers. Hematol Oncol Clinics North Am. 1996;10:1203-1213.
52. Stall RD, Greenwood GL, Acree M, et al. Cigarette smoking among gay and bisexual men. Am J Public Health. 1999;89:1875-1878.
53. Biggar R, Engels E, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr. 2005;39:293-299.
54. Voutsadakis IA, Silverman LR. Breast cancer in HIV-positive women: a report of four cases and review of the literature. Cancer Invest. 2002;20:452-457.
55. Guth AA. Breast cancer and HIV: what do we know? Am Surg. 1999;65:209-211.
56. Oluwole SF, Ali AO, Shafaee Z, et al. Breast cancer in women with HIV/AIDS: report of five cases with a review of the literature. J Surg Oncol. 2005;89:23-27.
57. Puoti M, Bruno R, Soriano V, et al. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS. 2004;18:2285-2293.
58. Crum NF, Spencer CR, Amling CL. Prostate carcinoma among men with human immunodeficiency virus infection. Cancer. 2004;101(2):294-299.
59. Lobo DV, Chu P, Grekin RC, et al. Nonmelanoma skin cancers and infection with human immunodeficiency virus. Arch Dermatol. 1992;128:623-627.
60. Smith KJ, Skelton HG, Yeager J, et al. Cutaneous neoplasms in a military population of HIV-1 positive patients. Military Medical Consortium for the Advancement of Retroviral Research. J Am Acad Dermatol. 1993;29:400-406.
61. Harwood CA, Surentheran T, McGregor JM, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol. 2000;61:289-297.
62. Salarieh A, Rao C, Gottesman S, et al. Plasma cell tumors in HIV-positive patients: report of a case and review of the literature. Leuk Lymphoma. 2005;46:1067-1074.
63. Whitman AG, Bryan BA, Dyson OF. AIDS related viruses, their association with leukemia, and Raf signaling. Curr HIV Res. 2005;3(4):319-327.
64. US Preventive Services Task Force (USPSTF) Screening Guidelines: Screening for Colorectal Cancer. Rockville, MD: US Dept of Health and Human Services, Agency for Healthcare Research and Quality; 2002. Available at: http://www.ahrq.gov/clinic/uspstf/uspscolo.htm. Accessed January 20, 2006.
65. Smith RA, Cijjubudes V, Harmon JE. American Cancer Society guidelines for early detection of cancer, 2003. CA Cancer J Clin. 2003;53:27-43.
66. Trubowitz P, Gates A, Kaplan L. Non-AIDS-defining malignancies. Sparano JA, eds. HIV and HTLV-1 Associated Malignancies. 1st ed. New York: Springer; 2001;303-328.
67. Lim ST, Levine AM. Non-AIDS-defining cancers and HIV infection. Curr HIV/AIDS Rep. 2005;2:146-153.
68. Kurman RJ, Henson DE, Herbst AL, et al. Interim guidelines for management of abnormal cervical cytology. 1992 National Cancer Institute Workshop. JAMA. 1994;271:1866-1869.
69. Goldie SJ, Freedberg KA, Weinstein MC, et al. Cost effectiveness of human papillomavirus testing to augment cervical cancer screening in women infected with the human immunodeficiency virus. Am J Med. 2001;111:140-149.
70. Goldie SJ, Kuntz KM, Weinstein MC, et al. The clinical effectiveness and cost-effectiveness of screening for anal squamous intraepithelial lesions in homosexual and bisexual HIV-positive men. JAMA. 1999;281:1822-1829.
71. Mulshine JL, Sullivan DC. Lung cancer screening. N Engl J Med. 2005;352:2714-2720.